×
About 2,855 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  911 results

Breast Cancer Recurrence after Smooth vs. Textured Implant-Based Breast Reconstruction:...
https://doi.org/10.1097/PRS.0000000000009491
Plastic and Reconstructive Surgery; Wu ZY, Han HH et. al.

Aug 10th, 2022 - An increasing number of reports on breast implant-associated anaplastic large cell lymphoma have recently raised concerns about the potential influence of breast implants on carcinogenicity, particularly implants with a textured surface. We compar...

Immunohistochemical Approach to Genetic Subtyping of Anaplastic Large Cell Lymphoma.
https://doi.org/10.1097/PAS.0000000000001941
The American Journal of Surgical Pathology; Feldman AL, Oishi N et. al.

Aug 9th, 2022 - Anaplastic large cell lymphoma (ALCL) can be classified genetically based on rearrangements (R) of the ALK, TP63, and/or DUSP22 genes. ALK-R defines a specific entity, ALK-positive ALCL, while DUSP22-R and TP63-R define subgroups of ALK-negative A...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Aug 5th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Transplantation After Complete Response In Patients With T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05444712

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Aug 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

see more →

Guidelines  6 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  78 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Aug 5th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Transplantation After Complete Response In Patients With T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05444712

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Aug 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
https://clinicaltrials.gov/ct2/show/NCT04881838

Jul 26th, 2022 - Anaplastic large cell lymphoma (ALCL) accounts for 15% of pediatric and adolescent non-Hodgkin lymphomas (NHLs). In our historical study (retrospective multicenter study), the 3-year event-free survival (EFS) was 65% for 80 eligible patients treat...

Vinorelbine for Recurrent ACLC
https://clinicaltrials.gov/ct2/show/NCT03397953

Jul 26th, 2022 - Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL e...

see more →

News  144 results

FDA OKs Crizotinib for Myofibroblastic Tumors 
https://www.medscape.com/viewarticle/977224

Jul 14th, 2022 - The US Food and Drug Administration (FDA) has approved crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work
https://www.medscape.com/viewarticle/961710

Oct 27th, 2021 - Takeda Pharmaceuticals is now the latest pharmaceutical company to offer a value-based agreement on one of its new targeted therapies. The rebate offer is for brigatinib (Alunbrig) which is approved for the treatment of adults with anaplastic lymp...

T-Cell Lymphoma Options Burgeoning With Ongoing Clinical Trials
https://www.onclive.com/view/tcell-lymphoma-options-burgeoning-with-ongoing-clinical-trials

Oct 6th, 2021 - Steven Horwitz, MD Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin (Adcetris) to improve outcomes for these patients. For example, the double-blind, randomized, multic...

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes
https://www.onclive.com/view/dr-jagadeesh-on-unmet-needs-in-aggressive-and-rare-lymphoma-subtypes

Oct 6th, 2021 - Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes. Most available therapies...

see more →